Mutations and chromosomal rearrangements of JAK2: Not only a myeloid issue

Expert Review of Hematology

Volumn 6, Issue 4, 2013, Pages 429-439

  Salmoiraghi, Silvia ^a   Guinea Montalvo, Marie Lorena ^a   D'Agostini, Elena ^b   Amicarelli, Giulia ^b   Minnucci, Giulia ^b   Spinelli, Orietta ^a   Rambaldi, Alessandro ^a  

^a Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

^b Diasorin SpA   (Italy)

Author keywords

acute leukemia; B chronic lymphocytic leukemia; JAK STAT pathway; JAK2; JAK2 inhibitors; lymphoma; myeloproliferative neoplasms

Indexed keywords

ACUTE DISEASE; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; HUMANS; JANUS KINASE 2; MUTATION; MYELOPROLIFERATIVE DISORDERS; POINT MUTATION; TRANSLOCATION, GENETIC;

EID: 84894096997     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2013.826910     Document Type: Review

References (91)

1. Ungureanu D, Wu J, Pekkala T et al. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat. Struct. Mol. Biol. 18(9), 971-976 (2011).
2. Khwaja A. The role of Janus kinases in haemopoiesis and haematological malignancy. Br. J. Haematol. 134(4), 366-384 (2006).
3. Ihle JN, Witthuhn BA, Quelle FW, Silvennoinen O, Tang B, Yi T. Protein tyrosine phosphorylation in the regulation of hematopoiesis by receptors of the cytokine-receptor superfamily. Blood Cells 20(1), 65-80, discussion 80-62 (1994).
4. James C, Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434(7037), 1144-1148 (2005).
5. Baxter EJ, Scott LM, Campbell PJ et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464), 1054-1061 (2005).
6. Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352(17), 1779-1790 (2005).
7. Levine RL, Wadleigh M, Cools J et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4), 387-397 (2005).
8. Zhao R, Xing S, Li Z et al. Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem. 280(24), 22788-22792 (2005).
9. Kota J, Caceres N, Constantinescu SN. Aberrant signal transduction pathways in myeloproliferative neoplasms. Leukemia 22(10), 1828-1840 (2008).
10. Vainchenker W, Constantinescu SN. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. Hematology Am. Soc. Hematol. Educ. Program. 195-200 (2005).
11. Scott LM, Tong W, Levine RL et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 356(5), 459-468 (2007).
12. Passamonti F, Elena C, Schnittger S et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 117(10), 2813-2816 (2011).
13. Ma W, Kantarjian H, Zhang X et al. JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms. PLoS ONE 5(8), e12165 (2010).
14. Mullighan CG. JAK2-a new player in acute lymphoblastic leukaemia. Lancet 372(9648), 1448-1450 (2008).
15. Lacronique V, Boureux A, Valle VD et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278(5341), 1309-1312 (1997).
16. Poitras JL, Dal Cin P, Aster JC, Deangelo DJ, Morton CC. Novel SSBP2-JAK2 fusion gene resulting from a t (5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia. Genes Chromosomes Cancer 47(10), 884-889 (2008).
17. Chen E, Staudt LM, Green AR. Janus kinase deregulation in leukemia and lymphoma. Immunity 36(4), 529-541 (2012).
18. Berger R, Le Coniat M, Lacronique V et al. Chromosome abnormalities of the short arm of chromosome 12 in hematopoietic malignancies: a report including three novel translocations involving the TEL/ETV6 gene. Leukemia 11(9), 1400-1403 (1997).
19. Peeters P, Raynaud SD, Cools J et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90(7), 2535-2540 (1997).
20. Reiter A, Walz C, Watmore A et al. The t (8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res. 65(7), 2662-2667 (2005).
21. Bousquet M, Quelen C, De Mas V et al. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene 24(48), 7248-7252 (2005).
22. Adelaide J, Perot C, Gelsi-Boyer V et al. A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma. Leukemia 20(3), 536-537 (2006).
23. Nebral K, Denk D, Attarbaschi A et al. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia 23(1), 134-143 (2009).
24. Coyaud E, Struski S, Prade N et al. Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study. Blood 115(15), 3089-3097 (2010).
25. Levine RL, Loriaux M, Huntly BJ et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 106(10), 3377-3379 (2005).
26. Jelinek J, Oki Y, Gharibyan V et al. JAK2 mutation 1849GT is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 106(10), 3370-3373 (2005).
27. Steensma DP, McClure RF, Karp JE et al. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia 20(6), 971-978 (2006).
28. Lee JW, Kim YG, Soung YH et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 25(9), 1434-1436 (2006).
29. Sulong S, Case M, Minto L, Wilkins B, Hall A, Irving J. The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia. Br. J. Haematol. 130(6), 964-965 (2005).
30. Kratz CP, Boll S, Kontny U, Schrappe M, Niemeyer CM, Stanulla M. Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia. Leukemia 20(2), 381-383 (2006).
31. Malinge S, Ben-Abdelali R, Settegrana C et al. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia 10.1182/blood-2006-09-045963. Blood 109(5), 2202-2204 (2007).
32. Bercovich D, Ganmore I, Scott LM et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 372(9648), 1484-1492 (2008).
33. Melzner I, Weniger MA, Menz CK, Moller P. Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma. Leukemia 20(1), 157-158 (2006).
34. Lee JW, Soung YH, Kim SY et al. JAK2 V617F mutation is uncommon in non-Hodgkin lymphomas. Leuk. Lymphoma 47(2), 313-314 (2006).
35. Mullally A, Ebert BL. Janus reveals another face: the biologic rationale for targeting Janus kinase 2 in lymphoma. J. Clin. Oncol. 30(33), 4168-4170 (2012).
36. Ekstrand BC, Horning SJ. Lymphocyte predominant Hodgkin's disease. Curr. Oncol. Rep. 4(5), 424-433 (2002).
37. Kuppers R. Molecular biology of Hodgkin lymphoma. Hematology Am. Soc. Hematol. Educ. Program 491-496 (2009).
38. Joos S, Kupper M, Ohl S et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res. 60(3), 549-552 (2000).
39. Joos S, Otano-Joos MI, Ziegler S et al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 87(4), 1571-1578 (1996).
40. Scarpa A, Taruscio D, Scardoni M et al. Nonrandom chromosomal imbalances in primary mediastinal B-cell lymphoma detected by arbitrarily primed PCR fingerprinting. Genes Chromosomes Cancer 26(3), 203-209 (1999).
41. Joos S, Granzow M, Holtgreve-Grez H et al. Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. Int. J. Cancer 103(4), 489-495 (2003).
42. Traverse-Glehen A, Pittaluga S, Gaulard P et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am. J. Surg. Pathol. 29(11), 1411-1421 (2005).
43. Eberle FC, Salaverria I, Steidl C et al. Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations. Mod. Pathol. 24(12), 1586-1597 (2011).
44. Jin L, Pahuja KB, Wickliffe KE et al. Ubiquitin-dependent regulation of COPII coat size and function. Nature 482(7386), 495-500 (2012).
45. Van Roosbroeck K, Cox L, Tousseyn T et al. JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma. Blood 117(15), 4056-4064 (2011).
46. Chim CS, Wong KY, Loong F, Srivastava G. SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak/STAT pathway. Leukemia 18(2), 356-358 (2004).
47. Melzner I, Bucur AJ, Bruderlein S et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood 105(6), 2535-2542 (2005).
48. Capello D, Gloghini A, Baldanzi G et al. Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma. Hematol. Oncol. 31(1), 22-28 (2013).
49. Calvo KR, Traverse-Glehen A, Pittaluga S, Jaffe ES. Molecular profiling provides evidence of primary mediastinal large B-cell lymphoma as a distinct entity related to classic Hodgkin lymphoma: implications for mediastinal gray zone lymphomas as an intermediate form of B-cell lymphoma. Adv. Anat. Pathol. 11(5), 227-238 (2004).
50. Mottok A, Renne C, Willenbrock K, Hansmann ML, Brauninger A. Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood 110(9), 3387-3390 (2007).
51. Patnaik MM, Knudson RA, Gangat N et al. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates. Eur. J. Haematol. 84(6), 518-524 (2010).
52. Lam LT, Wright G, Davis RE et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 111(7), 3701-3713 (2008).
53. Gupta M, Han JJ, Stenson M et al. Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. Blood 119(12), 2844-2853 (2012).
54. Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111(12), 5446-5456 (2008).
55. Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet 371(9617), 1017-1029 (2008).
56. Poulain S, Merchez M, Daudignon A, Simon M, Duthilleul P, Morel P. JAK2 V617F mutation is absent in chronic lymphocytic leukemia. Leuk. Lymphoma 47(12), 2657-2658 (2006).
57. Laurenti L, Tarnani M, Nichele I et al. The coexistence of chronic lymphocytic leukemia and myeloproliferative neoplasms: a retrospective multicentric GIMEMA experience. Am. J. Hematol. 86(12), 1007-1012 (2011).
58. Tabaczewski P, Nadesan S, Lim SH. Zap-70 positive chronic lymphocytic leukemia co-existing with Jak 2 V671F positive essential thrombocythemia: a common defective stem cell? Leuk. Res. 33(6), 854-855 (2009).
59. Henry L, Carillo S, Jourdan E, Arnaud A, Brun S, Lavabre-Bertrand T. Association of essential thrombocythemia and chronic lymphocytic leukemia: absence of the V617F JAK2 mutation in the lymphoid compartment. Am. J. Hematol. 82(6), 500-501 (2007).
60. Hussein K, Brakensiek K, Ballmaier M et al. B-CLL developing in a patient with PV is not affected by V617F mutation of the Janus kinase 2. Eur. J. Haematol. 77(6), 539-541 (2006).
61. Wei J, Wang C, Qin YW et al. JAK2 V617F positive essential thrombocythemia developing in a patient with CD5(-) chronic lymphocytic leukemia. Chin. Med. J. (Engl.) 125(11), 2076-2079 (2012).
62. Musolino C, Allegra A, Penna G et al. Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders. Acta Haematol. 122(1), 46-49 (2009).
63. Swierczek S, Nausova J, Jelinek J et al. Concomitant JAK2 V617F-positive polycythemia vera and B-cell chronic lymphocytic leukemia in three patients originating from two separate hematopoietic stem cells. Am. J. Hematol. 88(2), 157-158 (2013).
64. Stijnis C, Kroes WG, Balkassmi S et al. No evidence for JAK2(V617F) mutation in monoclonal B cells in 2 patients with polycythaemia vera and concurrent monoclonal B cell disorder. Acta Haematol. 128(3), 183-186 (2012).
65. Kodali S, Chen C, Rathnasabapathy C, Wang JC. JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN). Leuk. Res. 33(12), e236-e239 (2009).
66. Sidon P, El Housni H, Dessars B, Heimann P. The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia 20(9), 1622 (2006).
67. Xu X, Zhang Q, Luo J et al. JAK2(V617F): Prevalence in a large Chinese hospital population. Blood 109(1), 339-342 (2007).
68. Jovanovic JV, Vannucchi, AM, Lippert E et al. Systematic evaluation of DNA-based quantitative-polymerase chain reaction (QPCR) assays to track treatment response in patients with JAK2-V617F associated myeloproliferative neoplasms: a Joint European LeukemiaNet/MPN&MPNr-EuroNet study. Blood 118 (2011).
69. Bench AJ, White HE, Foroni L et al. Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. Br. J. Haematol. 160(1), 25-34 (2013).
70. Minnucci G, Amicarelli G, Salmoiraghi S et al. A novel, highly sensitive and rapid allele-specific loop-mediated amplification assay for the detection of the JAK2V617F mutation in chronic myeloproliferative neoplasms. Haematologica 97(9), 1394-1400 (2012).
71. Minnucci G, Amicarelli G, D'Agostini E et al. A real-time monitoring of JAK2V617F mutation by ultra-rapid, high sensitive fluorescent AS-LAMP. 17th Congress of EHA Abstract Book (2012).
72. Hauck G, Jonigk D, Kreipe H, Hussein K. Simultaneous and sequential concurrent myeloproliferative and lymphoproliferative neoplasms. Acta Haematol. 129(3), 187-196 (2013).
73. Olcaydu D, Harutyunyan A, Jager R et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat. Genet. 41(4), 450-454 (2009).
74. Kilpivaara O, Mukherjee S, Schram AM et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat. Genet. 41(4), 455-459 (2009).
75. Jones AV, Chase A, Silver RT et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat. Genet. 41(4), 446-449 (2009).
76. Olcaydu D, Skoda RC, Looser R et al. The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia 23(10), 1924-1926 (2009).
77. Tefferi A, Lasho TL, Patnaik MM et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia 24(1), 105-109 (2010).
78. Olcaydu D, Rumi E, Harutyunyan A et al. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Haematologica 96(3), 367-374 (2011).
79. Rumi E, Passamonti F, Elena C et al. Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. Haematologica 96(3), 454-458 (2011).
80. Passamonti F, Maffioli M, Caramazza D. New generation small-molecule inhibitors in myeloproliferative neoplasms. Curr. Opin. Hematol. 19(2), 117-123 (2012).
81. Verstovsek S, Kantarjian H, Mesa RA et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 363(12), 1117-1127 (2010).
82. Verstovsek S, Kantarjian HM, Estrov Z et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 120(6), 1202-1209 (2012).
83. Verstovsek S. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis. Postgrad. Med. 125(1), 128-135 (2013).
84. Lierman E, Selleslag D, Smits S, Billiet J, Vandenberghe P. Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia. Blood 120(7), 1529-1531 (2012).
85. Rumi E, Milosevic JD, Casetti I et al. Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. J. Clin. Oncol. 31(17), e269-e271 (2013).
86. Chase A, Bryant C, Score J et al. Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements. Haematologica 98(3), 404-408 (2012).
87. Diaz T, Navarro A, Ferrer G et al. Lestaurtinib inhibition of the Jak/STAT signaling pathway in Hodgkin lymphoma inhibits proliferation and induces apoptosis. PLoS ONE 6(4), e18856 (2011).
88. Derenzini E, Lemoine M, Buglio D et al. The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. Blood Cancer J. 1(12), e46 (2011).
89. Younes A, Romaguera J, Fanale M et al. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J. Clin. Oncol. 30(33), 4161-4167 (2012).
90. Younes A, Bartlett NL, Leonard JP et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 363(19), 1812-1821 (2010).
91. Dunleavy K, Pittaluga S, Maeda LS et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N. Engl. J. Med. 368(15), 1408-1416 (2013).